Mean Platelet Volume on Systemic Lupus Erythematosus Patients with and without Thrombocytopenia in Dr Hasan Sadikin Hospital Bandung: A Descriptive Study by Philo, Patrick et al.
Original Article 
 
Mean Platelet Volume on Systemic Lupus 
Erythematosus Patients with and Without 
Thrombocytopenia in Dr Hasan Sadikin 
Hospital Bandung : a Descriptive Study 
 
Patrick Philo1, Dewi Kartika Turbawaty2, Laniyati Hamijoyo3 
 
 




2 Department of Clinical 





3 Department of 
Internal Medicine, 
Rheumatology 












Background : The aim of the study was to provide 
an insight about mean platelet volume (MPV) value in 
systemic lupus erythematosus (SLE) with and without 
thrombocytopenia patient. MPV was expected to be 
used to determine the cause thrombocytopenia in 
lupus, so the patient could be treated appropriately.  
Method : The study design was descriptive categoric, 
and the data were obtained by using cross-sectional 
method from patient’s medical record and lab 
examination result in the period from January 1st 2016 
– January 31st 2018. The sampling method are done 
using total sampling. The inclusion criteria of this study 
were SLE patients diagnosed with SLE ACR (American 
College of Rheumatology) Criteria 1997, which MPV 
and platelet count had been examined at the same 
time, the data used is data that was first discovered in 
the period of the study. The exclusion criteria were 
incomplete medical record data (the data needed for 
patient’s characteristic wasn’t recorded), patient with 
thrombocytosis, and SLE with comorbidity such as 
thrombotic disease (ischemic stroke and deep vein 
thrombosis), other high inflammatory overlap diseases 
(such as rheumatoid arthritis and inflammatory bowel 
disease), and infection. 
Result : From 75 patients that match with the inclusion 
criteria, all patients were female and based on the age of 
diagnosis, most patients were in age group of 25-34 
years old (41,33%). Based on the lab results, group with 
normal platelet count have 53 (70,7%) subjects of normal 
MPV and 12 (16%) subjects of high MPV, while group 
with thrombocytopenia have 6 (8%) subjects of normal 
MPV and 4 (5,3%) subjects of high MPV. Conclusion : 
Group with normal MPV value and normal platelet count 
has the largest proportion, while the group with 
thrombocytopenia in lupus and high MPV value has the 
lowest proportion. 
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Systemic Lupus Erythematosus (SLE) is an 
autoimmune disease with a wide spectrum of 
clinical manifestations and involving the role of 
autoantibodies. Tissue injury is mainly mediated 
 
 
by deposition of immune complex and binding of 
antibodies to a wide variation of body tissue. This 
disease is characterized by its chronic nature and 
has remitting and relapsing phase. 1,2  
Lupus has broad spectrum of clinical 
manifestations such as skin and mucosal, joint, 
blood, lungs, heart, renal, nervous system, and 
immune system involvement.3 Thrombocytopenia, 
which generally defined by platelet count below 
150.000/mm3, is one of the haematological 
manifestation that commonly occurs in SLE 
patient.4,5 The low platelet count may affect 
thrombocyte volume in an inverse relationship to 
maintain constant thrombocyte mass.6 
Thrombocytopenia in lupus may appear because of 
thrombocyte destruction mediated by antiplatelet 
antibodies, on the other hand, thrombocytopenia 
may also occur as the side effect of 
immunosuppressant medication. It is difficult to 
determine whether the occurence of 
thrombocytopenia in lupus arise due to disease 
activity or as a side effect of medication. 7,8  
The average thrombocyte volume in the 
circulation can be measured with Mean Platelet 
Volume (MPV) examination, with the normal 
range of 7,5-11,5 fL.9 MPV value in SLE patient 
commonly associated with its inflammation degree, 
while in thrombocytopenia, MPV value may be 
used to differentiate its etiology (hyperdestructive 
or hypoproductive).6, 10  
Previous study had shown the role of MPV in 
differentiating the etiology of thrombocytopenia.10 
Therefore, it might be used to identify the cause of 
thrombocytopenia in lupus. However, the study 
about MPV value on thrombocytopenia in lupus 
patient haven’t been done, so there isn’t any valid 
data yet. Besides, the study about MPV value on 
SLE patient has only been conducted abroad, hence 
there isn’t any proven data in Indonesia so far. The 
aim of the study is to provide an insight about MPV 
value in SLE patient with and without 
thrombocytopenia. Hopefully, MPV was expected 
to be used to determine the cause of 
thrombocytopenia in lupus in the future, so the 
patient could be treated appropriately. 
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Method 
The study design was descriptive categoric, and the data were 
obtained by using cross-sectional method. The study was 
conducted in June-August 2018 using secondary data of the 
inpatient and outpatient medical record in the medical record 
installation, result of the laboratory examination in clinical 
pathology laboratorium, and Lupus Registry in Immunology 
Study Centre in Dr. Hasan Sadikin Hospital Bandung from 
January 2016-2018. The population of this study were SLE 
patient registered at lupus registry in immunology study centre 
and at rheumatology division of internal medicine department Dr. 
Hasan Sadikin Hospital Bandung in the period of January 1st 2016 
– January 31st 2018. Data collection technique in this study was 
total sampling method. The inclusion criteria of this study were 
SLE patients diagnosed with SLE ACR (American College of 
Rheumatology) Criteria 1997, which MPV and platelet count had 
been examined at the same time, the data used is data that was 
first discovered in the period of the study. The exclusion criteria 
were incomplete medical record data (the data needed for 
patient’s characteristic wasn’t recorded), patient with 
thrombocytosis, and SLE with comorbidity such as thrombotic 
disease (ischemic stroke and deep vein thrombosis), other high 
inflammatory overlap diseases (such as rheumatoid arthritis and 
inflammatory bowel disease), and infection. 
 
MPV and platelet count were measured using Sysmex XN-
1000 with the flow cytometry principle. The reference value 
used in the study was based on the Clinical Pathology 
Laboratory at Dr. Hasan Sadikin Hospital Bandung with value 
of 7,2-11,1 fL and 150.000-450.000/mm3 respectively for 
MPV and platelet count.  
This study had been approved by the Research Ethical 
Committee of Universitas Padjadjaran, Bandung through the 
letter of approval Number 183/UN6.KEP/EC/2018. Data were 
collected from the patient’s MPV and platelet count result, 
then the data was categorized based on the MPV (low, normal, 
high) and platelet count (normal and thrombocytopenia) 
interpretation. Demographical data were obtained from 
medical record and lupus registry. Data analyzed using 
descriptive statistic, processed using Microsoft Excel 2016 
and presented in tables and percentage. 
 
Results 
During the period between January 1st 2016- January 31st 
2018, 104 SLE patients with 114 laboratory examination 
results were collected and fulfilled the inclusion criteria of this 
study. As many as 39 data among the 114 lab result were met 
the exclusion criteria, with 27 data were excluded due to 
infection, 12 data excluded due to thrombosis disease, 
thrombocytosis, and incomplete medical record data. 
Therefore, there were 75 SLE patients and lab examination 
results which included in this study. 
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Table 1. Characteristics of study’s subject  
    
 Variable Subject (n=75) Percentage (%) 
Gender   
• Female 75 100 
Age at diagnosis   
• <15 years old 3 4 
• 15-24 years old 28 37,4 
• 25-34 years old 31 41,3 
• 35-44 years old 10 13,3 
• 45-54 years old 3 4  
 
 Variable Subject (n=75) Percentage (%) 
Duration of patient   
diagnosed with SLE until   
MPV and platelet count   
examination are conducted   
• 0-2 years 43 57,3 
• 3-4 years 12 16 
• 5-6 years 5 6,7 
• 7-8 years 6 8 
• > 8 years 9 12 
 
The study show that all subject of this study (100%) are 
female, and most subject are diagnosed with SLE at the age group 
of 25-34 years old (41,3%), followed by age group 15-24 years 
old (37,4%). Based on the duration of patient diagnosed with SLE 
until laboratory examination are conducted, most subject are 
having laboratory examination in 0-2 years (57,3%) and 3-4 years 
after diagnosed with SLE (16%). 
 
Table 2. Mean Platelet Volume Value of SLE Patient in Hasan 
Sadikin Hospital between January 1st 2016 – January 31st 2018 
Mean Platelet Volume N=75 % 
Normal 59 78,7% 
High 16 21,3% 
Total 75 100%  
*Reference Value : Normal (7,2-11,1 fL), High (>11,1 fL) 
 
Table 3. Platelet Count Value of SLE Patient in Hasan Sadikin 
Hospital between January 1st 2016 – January 31st 2018 
Platelet Count N=75 % 
Normal 65 86,7% 
Thrombocytopenia 10 13,3% 
Total 75 100%  
*Reference Value : Normal (150.000-450.000/mm3), 
Thrombocytopenia (<150.000/mm3) 
 
Table 4. Mean Platelet Volume Value of SLE Patient 
with & without thrombocytopenia in Hasan Sadikin 
Hospital between January 1st 2016 – January 31st 2018  
  Platelet Count (n = 75)  
  Thrombocytopenia Normal Total 
Mean Normal 6 (8%) 53 (70,7%) 59 (78,7%) 
Platelet 
High 4 (5,3%) 12 (16%) 16 (21,3%) 
Volume      
(n=75)      
 Total 10 (13,3%) 65 (86,7%) 75 (100%) 
Original Article 
 
Among 75 lab examination data, normal MPV value are 
found in 59 subjects (78,7%) and the other 16 subjects 
(21,3%) have a high MPV value, while normal platelet count 
are found in 65 subjects (86,7%) and 10 subjects (13,3%) have 
thrombocytopenia. Among 65 subjects with normal platelet 
count, 53 subjects (70,7%) have normal MPV value and 12 
subjects (16%) have high MPV value, whereas the other 10 
subjects with thrombocytopenia, normal MPV value are found 




From this study, it was found that all subjects of this study 
(100%) were female and 31 patient (41,3%) among them were 
diagnosed at the age of 25-34 years old. This result is similar 
with the study from Rupert W. Jakes et al in South-East Asia 
(2012) who reported that 83-97% of SLE patient in South-East 
Asia are female, with the mean age of 25,7 - 35,4 years old 
when diagnosed.11 Another study conducted by F Ress et al 
(2017) also stated that the prevalence of SLE is higher in 
woman at reproductive age than man with the ratio of 1,2 – 
15: 1 globally. 12  
Hormone regulation and its effect to cytokine production, 
along with chromosomal factor, play a central role in causing the 
high proportion of SLE in woman at reproductive age. Estrogen 
and Prolactin are capable to stimulate autoreactive B Lymphocyte 
cell, hence leading to loss of immune tolerance and secretion of 
autoantibody.13 On the other hand, Androgen and Testosterone 
have protective nature to autoimmune disease, because both are 
natural immunosuppressant. 14  
Haematological abnormality (thrombocytopenia, anemia, 
leucopenia) is a common manifestation of SLE, it may appear on 
the onset disease or develop along the disease course, as the 
consequence of disease activity or induced by drugs.8,15 In this 
study, “duration of patient diagnosed with SLE until laboratory 
examination are conducted” refer to duration of patient diagnosed 
with SLE until the occurence of haematological manifestation, 
because MPV and platelet count only done on SLE patient with 
haematological abnormality in Hasan Sadikin hospital. This 
study showed that most subject are having MPV and platelet 
count examination conducted in the first 2 years (57,3%) after 
diagnosed. The result is equal with the study of Aamer Aleem et 
al in Arab Saudi (2014) who reported that 516 (82,7%) out of 624 
SLE patients are having haematological manifestation at the 
onset of diagnosis.16 High frequency of haematological 
manifestation in SLE patient is caused by many and varied 
antigens on blood cells and blood vessels. In autoimmune case, 
autoantibody will be produced against self-antigen, including 
blood cells, and haematological abnormality will appear through 
inflammation. 17, 18  
MPV has an important role in high inflammatory disease like 
SLE and rheumatoid arthritis, it might be used as a marker of 
inflammation degree, a marker of disease activity, and to measure 
the efficacy of antiinflammatory therapy in some inflammatory 
disease.6 The MPV value of SLE patient without 
thrombocytopenia in this study were normal in 53 subjects 
(70,7%) and high in 12 subjects (16%). This result resembles the 
research done by Sun-Yi Chen et al in China (2018) who 
 
 
found 91 SLE patients have mean MPV value of 10,74±0,94 fL 
(International Reference : 7,2-11,5 fL), which interpreted to 
normal-high. This result is lower than the control (mean MPV  
= 11,09±1,14 fL), which show the effect of inflammation on  
MPV value. 19  
The role of MPV as the marker of inflammation degree and 
disease activity also illustrated by the study of Sahin Safak et al 
in Turkey (2014) who conclude that MPV value of group with 
active arthritis is lower than the group with inactive arthritis, 
while the control group have the highest value.20 Similar result 
also stated by the study conducted by Guillermo Delgado-García 
et al in Mexico (2016), who showed that a group of patients with 
active SLE have a lower MPV value (MPV = 7,16±1,39) than a 
group of SLE patients whose disease are at remission (MPV = 
8,16±1,50).21 In high inflammatory disease like SLE, MPV has a 
low value because there is an increase in inflammatory cytokine 
production like IL-3 and IL-6, which will boost the 
thrombopoiesis (thrombocyte production). The process will result 
in large thrombocyte, but this large thrombocyte will be 
consumed at the site of inflammation, hence only small 
thrombocyte left in the circulation. 6, 19  
The MPV value of thrombocytopenia in lupus patient this 
study showed normal in 6 subjects (8%) and high in 4 subjects 
(5,3%). This result unabled to be compared, because there was 
not any preliminary research about MPV value on 
thrombocytopenia in lupus patient. However, MPV can be used 
to distinguish thrombocytopenia based on its cause. MPV value 
tend to be higher on thrombocytopenia caused by excess platelet 
destruction (hyperdestructive thrombocytopenia) like immune 
thrombocytopenic purpura, disseminated intravascular 
coagulation, sepsis, and preeclampsia. While MPV value is prone 
to be lower on thrombocytopenia caused by reduced thrombocyte 
production (Hypoproductive Thrombocytopenia) like aplastic 
anemia. 9, 22  
The difference in MPV value on thrombocytopenia based on 
its etiology was suitable with the result of the study conducted by 
Numbenjapon et al in Thailand (2008). Among 62 patients with 
hyperdestructive thrombocytopenia, 51 subjects have  
MPV value > 7,9 fL and 11 other have MPV value ≤7,9 fL.  
From 40 patients with hypoproductive thrombocytopenia, 37 
subjects have MPV value ≤7,9 fL, while the rest have MPV 
value > 7,9 fL. The result shows that group of hyperdestructive 
thrombocytopenia have a higher MPV value than group of 
hypoproductive thrombocytopenia.22 The distinction in MPV 
value may occur because in hyperdestructive case, excess 
platelet destruction will lead to compensation from bone 
marrow to boost the platelet production, so that large 
thrombocyte will be produced. 10  
Thrombocytopenia is a common manifestation found in SLE 
patient and also one of the criteria for diagnosis of SLE.7 
Thrombocytopenia usually appear through autoimmune 
mechanism similar to immune thrombocytopenic purpura and 
mediated by antiplatelet, but it may also emerge as a side effect 
of immunosuppressant therapy (methotrexate, 
cyclophosphamide, azathioprine, and hydroxychloroquine). 8,23 
However, it is still difficult to distinguish between 
thrombocytopenia in lupus caused by disease activity or side 
effect of therapy.7 Although there isn’t any preliminary 
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study about MPV value on thrombocytopenia in 
lupus patient, the prove that MPV can differentiate 
the cause of thrombocytopenia can be the first step 
in order to use MPV to distinguish the cause of 
thrombocytopenia in lupus patient, so that the 
patient can get appropriate treatment.  
In this study, there was not any data with low MPV 
value. Theoretically, high disease activity is associated 
with high inflammatory degree that cause consumption 
of large thrombocyte and left small thrombocyte in 
circulation, which lead to lower MPV value.6 Study 
conducted by Sahin Safak et al in Turkey showed the 
MPV value of SLE patients with active arthritis are 
7,66±0,89 (low - normal).20 Research done by 
Guillermo Delgado-García et al in Mexico also proved 
that patients with active SLE have a low MPV value 
(7,16±1,39), with the disease activity measured using 
Mex-SLEDAI (Mexican Systemic Lupus 
Erythematosus Disease Activity Index). Patient stated 
active if the Mex-SLEDAI score > 5 and inactive if the 
Mex-SLEDAI socre < 2. 21 The differences in this study 
and the previous study might be caused by the 
limitation of this study, that in this study there were not 
any data about patient’s disease activity, so that the 
laboratory result could not be adjusted with the disease 
activity. Besides, there are other factors that can 
interfere with the MPV value such as improper storage 
of blood samples, the use of antiinflammatory drugs, 
the probabilty of emergence of other comorbidity, 
presence of cardiovascular risk factor (smoking, 
hypertension, diabetes mellitus, obesity, and 
dyslipidemia), and the use of antihypertension.6,24 
These factors are less noticed by author, so they could 
become limitations in this study, beside limited subject 
and incomplete data. 
 
Conclusion 
Lupus patient with both normal MPV value and 
normal platelet count has the largest proportion, 
while the group with thrombocytopenia and high 
MPV value has the lowest proportion.  
Subsequent research could use primary data and 
focus on proving MPV value to distinguish the cause 
of thrombocytopenia in lupus, so that the patient can 
get appropriate therapy in the future. 
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